Patients of the Unified Health System (SUS) of Paraná who have refractory epilepsy will now have access to medications made from cannabidiol (CBD). The Paraná State Health Department (Sesa) regulated, this Monday, 23, the provision of medication to treat the disease.
Registration for treatment requests will open in July. The supply will be directed to patients diagnosed with Dravet and Lennox-Gastaut syndromes and tuberous sclerosis complex, rare neurological conditions, when there is no response to conventional therapies.
With proven efficacy and safety, the medicine is now offered by Sesa exclusively for the indications provided for in the package insert and for patients whose therapeutic options available in the SUS have already been exhausted.
Since the beginning of 2025, Paraná has been offering the drug with a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) to patients with moderate to severe spasticity associated with multiple sclerosis.
Currently, 69 patients are registered to receive the treatment, which is available in the state public network and in the municipalities responsible for dispensing specialized medications. Access is governed by Sesa Resolution No. 1.180/2024.
Advances in treatment
For the State Secretary of Health, Beto Preto, the release of cannabidiol in the SUS of Paraná for specific cases of refractory epilepsy represents an advance in the care of people who face these syndromes with an enormous impact on quality of life.
According to Sesa, the clinical criteria for access to treatment are set out in Sesa Resolutions No. 1.078, No. 1.080 and No. 1.081 (see all of them). HERE).
Patients interested in treatment will be able to present the required documentation, starting next month, directly at pharmacies in the health regions or municipalities that are part of the specialized component and the complementary list of the department.
The list of required documents can be consulted HERE.
The new measure is based on scientific evidence that proves the efficacy and safety of the medication for these specific indications, as established in the package insert.
The offer follows the parameters defined by State Law No. 21.364/2023, regulated by decrees No. 4.977/2024 and No. 10.222/2025.
(With information from the State News Agency)
